See more : IPE Universal Inc. (IPEU) Income Statement Analysis – Financial Results
Complete financial analysis of Merrimack Pharmaceuticals, Inc. (MACK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merrimack Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hotel Shilla Co.,Ltd (008775.KS) Income Statement Analysis – Financial Results
- Las Vegas Sands Corp. (0QY4.L) Income Statement Analysis – Financial Results
- Takuni Group Public Company Limited (TAKUNI.BK) Income Statement Analysis – Financial Results
- Reed’s, Inc. (REED) Income Statement Analysis – Financial Results
- New Nordic Healthbrands AB (publ) (NNH.ST) Income Statement Analysis – Financial Results
Merrimack Pharmaceuticals, Inc. (MACK)
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 144.27M | 89.26M | 102.76M | 47.79M | 48.92M | 34.22M | 20.31M | 2.15M |
| Cost of Revenue | 0.00 | 445.00K | 0.00 | 0.00 | 2.23M | 0.00 | 0.00 | 6.91M | 46.00K | 0.00 | 0.00 | 0.00 | 100.63M | 58.28M | 37.66M |
| Gross Profit | 0.00 | -445.00K | 0.00 | 0.00 | -2.23M | 0.00 | 0.00 | 137.36M | 89.21M | 102.76M | 47.79M | 48.92M | -66.42M | -37.97M | -35.51M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 95.21% | 99.95% | 100.00% | 100.00% | 100.00% | -194.11% | -187.01% | -1,653.17% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 11.10M | 49.97M | 67.31M | 160.92M | 160.99M | 138.50M | 147.14M | 125.86M | 365.00K | 0.00 | 0.00 |
| General & Administrative | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 0.00 | 0.00 | 30.52M | 21.19M | 15.81M | 8.84M | 0.00 | 0.00 |
| Selling & Marketing | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.62M | 0.00 | 0.00 |
| SG&A | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 80.73M | 57.60M | 30.52M | 21.19M | 15.81M | 14.45M | 11.38M | 12.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -191.00K | 370.00K | -3.23M | -1.43M | -43.38M | -18.22M | -17.30M | -10.15M | 988.00K | 34.16M | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 241.65M | 218.58M | 169.01M | 168.33M | 141.66M | 14.45M | 11.38M | 12.18M |
| Cost & Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 248.56M | 218.63M | 169.01M | 168.33M | 141.66M | 115.08M | 69.66M | 49.84M |
| Interest Income | 868.00K | 188.00K | 20.00K | 50.00K | 777.00K | 1.30M | 895.00K | 276.00K | 99.00K | 114.00K | 166.00K | 184.00K | 56.00K | 74.00K | 81.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.53M | 956.00K | 34.65M | 43.65M | 19.23M | 18.23M | 10.94M | 553.00K | 13.00K | 3.73M | 4.91M |
| Depreciation & Amortization | 167.90K | -890.00K | -288.00K | -2.28M | -1.54M | 4.07M | 5.22M | 6.25M | 4.29M | 3.22M | 2.59M | 3.66M | 5.33M | 4.38M | 2.76M |
| EBITDA | -2.18M | -2.62M | -2.76M | -5.15M | -20.26M | -65.58M | -91.08M | -110.14M | -125.28M | -66.26M | -120.54M | -92.74M | -75.49M | -44.90M | -44.85M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -68.22% | -144.94% | -64.48% | -252.25% | -189.58% | -220.63% | -221.13% | -2,088.08% |
| Operating Income | -2.18M | -1.73M | -2.47M | -2.87M | -22.36M | -65.58M | -95.77M | -110.14M | -129.57M | -66.26M | -120.54M | -92.74M | -80.87M | -49.18M | -47.69M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.34% | -145.16% | -64.48% | -252.25% | -189.58% | -236.36% | -242.19% | -2,220.11% |
| Total Other Income/Expenses | 1.01M | 188.00K | 20.00K | -141.00K | -381.00K | -2.89M | -22.64M | -43.38M | -18.22M | -17.30M | -10.15M | 1.47M | 1.19M | -983.00K | -4.79M |
| Income Before Tax | -1.17M | -1.54M | -2.45M | -3.01M | -22.74M | -68.46M | -118.40M | -153.52M | -147.79M | -83.56M | -130.69M | -91.75M | -79.68M | -50.16M | -52.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.41% | -165.57% | -81.32% | -273.48% | -187.56% | -232.87% | -247.03% | -2,442.97% |
| Income Tax Expense | 12.00K | 3.00K | 3.00K | 14.00K | -1.47M | -7.70M | -42.40M | -13.22M | -3.92M | -3.49M | -2.35M | -4.14M | -440.00K | 3.67M | -3.40M |
| Net Income | -1.18M | -1.54M | -2.46M | -3.03M | -21.27M | -40.51M | 472.03M | -151.74M | -147.96M | -83.29M | -130.93M | -91.28M | -79.22M | -50.10M | -49.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -105.18% | -165.76% | -81.06% | -273.98% | -186.58% | -231.54% | -246.76% | -2,284.59% |
| EPS | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| EPS Diluted | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| Weighted Avg Shares Out | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
| Weighted Avg Shares Out (Dil) | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend...
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of...
Merrimack Receives $225 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and...
Merrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2023 Financial Results.
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) reported that Ipsen, SA (“Ipsen”) issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection)...
Merrimack Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Third Quarter 2023 Financial Results.
Merrimack Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2023 Financial Results.
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the...
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has been invited...
Nuss Truck & Equipment Launches e-Emphasys Dealer Management Platform
CARY, N.C.--(BUSINESS WIRE)--e-Emphasys Technologies Inc., a global enterprise software provider for the heavy equipment and industrial machinery industry, today announced that Nuss Truck & Equipment, one of the largest providers of trucks, trailers and heavy equipment in the Midwestern United...
Source: https://incomestatements.info
Category: Stock Reports